**In the Claims:**

This listing of claims will replace all prior versions, and listings of the claims in the application.

Please amend claims 1-5 and 8, cancel claims 7 and 9-13 without prejudice to their presentation in another application, and add new claims 14-29 as follows.

1. (currently amended) A compound in accord with formula I:



I

wherein:

$R^1$ at each occurrence is ~~a moiety~~ independently selected from CN, $CF_3$, $OCF_3$, $OCHF_2$, halogen, $C_{1-4}$alkyl, $C_{2-4}$alkenyl, $C_{2-4}$alkynyl, $R^a$, $R^b$, $SR^a$, $NR^eR^f$, $CH_2NR^eR^f$, $OR^c$, and $CH_2OR^c$, where m is ~~selected from~~ 0, 1, 2 or 3; wherein $R^a$, $R^b$, and $R^c$ are independently at each occurrence selected from hydrogen, $C_{1-6}$alkyl, $C(O)R^d$, $C(O)NHR^d$ and $CO_2R^d$, or $R^a$ and $R^b$ may together be $(CH_2)_jG(CH_2)_k$ or $G(CH_2)_jG$ where G is oxygen, j is 1, 2, 3 or 4, k is 0, 1 or 2; where $R^d$ at each occurrence is independently selected from $C_{1-6}$alkyl, and $R^e$ and $R^f$ are independently at each occurrence selected from hydrogen, $C_{1-6}$alkyl, $C(O)R^d$, $C(O)NHR^d$, and $CO_2R^d$;

$R^2$ at each occurrence is ~~a moiety~~ independently selected from CN, $CF_3$, $OCF_3$, $OCHF_2$, halogen, $C_{1-4}$alkyl, $C_{2-4}$alkenyl, $C_{2-4}$alkynyl, $R^a$, $R^b$, $SR^a$, $NR^eR^f$, $CH_2NR^eR^f$, $OR^c$, and $CH_2OR^c$, where m is ~~selected from~~ 0,1, 2 or 3; wherein $R^a$, $R^b$, and $R^c$ are independently at each occurrence selected from hydrogen, $C_{1-6}$alkyl, $C(O)R^d$, $C(O)NHR^d$ and $CO_2R^d$, or $R^a$ and $R^b$ may together be $(CH_2)_jG(CH_2)_k$ or $G(CH_2)_jG$ where G is oxygen, j is 1, 2, 3 or 4, k is 0, 1 or

2; where $R^d$ at each occurrence is independently selected from $C_{1-6}$alkyl, and $R^c$ and $R^f$ are independently at each occurrence selected from hydrogen, $C_{1-6}$alkyl, C(O)$R^d$, C(O)NH$R^d$, and $CO_2R^d$;

$R^3$ is selected from hydrogen, $C_{1-6}$alkyl, C(O)-$(CH_2)_q$-$NR^8R^9$, $(CH_2)_r$-$NR^8R^9$, $(CH_2)_q$-O-D, $(CH_2)_q$-D and $(CH_2)_q$-CH=CH-D, wherein $R^8$ and $R^9$ are independently selected from hydrogen and $C_{1-6}$alkyl, q is ~~selected from~~ 1, 2 or 3, r is ~~selected from~~ 1,2, 3 or 4 and D is ~~selected from~~ phenyl or indolyl which phenyl or indolyl may bear one or more substituents selected from halogen, $C_{1-6}$alkyl, $C_{1-6}$alkoxy and -O-$(CH2)_q$-O-;

$R^4$, $R^5$, $R^6$ and $R^7$ at each occurrence are independently ~~selected from~~ hydrogen or $C_{1-6}$alkyl[[,]] ; or

independently, $R^4$ and $R^5$ together with the carbon to which they are attached and $R^6$ and $R^7$ together with the carbon to which they are attached form a moiety in accord with formula II,


wherein p is ~~selected from~~ 0, 1, 2, 3 or 4; or

~~*in vivo* hydrolysable precursors thereof, and~~ or a pharmaceutically-acceptable ~~salts~~ salt thereof.

2. (currently amended) A compound according to Claim 1, wherein:

$R^1$ at each occurrence is independently selected from fluoro, cyano, $C_{1-6}$alkyl and $C_{1-6}$alkoxy and m is 1, 2 or 3;

$R^2$ at each occurrence is independently selected from halogen where n is 1 or 2, and

$R^3$ is selected from hydrogen and $C_{1-6}$alkyl;

~~*in vivo* hydrolysable precursors thereof, and~~ or a pharmaceutically-acceptable ~~salts~~ salt thereof.

3. (currently amended) A compound according to Claim 1, wherein:

$R^1$ at each occurrence is independently selected from fluoro, cyano, ethyl and methoxy

and m is 1, 2 or 3;

$R^2$ at each occurrence is independently selected from halogen where n is 1 or 2, and

$R^3$ is selected from hydrogen and methyl;

~~*in vivo* hydrolysable precursors thereof, and~~ or a pharmaceutically-acceptable ~~salts~~ salt thereof.

4. (currently amended) A compound according to Claim 1, wherein $R^4$, $R^5$ and $R^6$ are each hydrogen and $R^7$ is methyl; ~~*in vivo* hydrolysable precursors thereof, and~~ or a pharmaceutically-acceptable ~~salts~~ salt thereof.

5. (currently amended) A compound according to Claim 1, wherein:

$R^1$ at each occurrence is independently selected from fluoro, cyano, $C_{1-6}$alkyl and $C_{1-6}$alkoxy and m is 1, 2 or 3;

$R^2$ at each occurrence is independently selected from halogen where n is 1 or 2, and

$R^3$ is selected from hydrogen, $C_{1-6}$alkyl, $C(O)$-$(CH_2)_q$-$NR^8R^9$, $(CH_2)_r$-$NR^8R^9$, $(CH2)_q$-O-D, wherein $R^8$ and $R^9$ are independently selected from hydrogen, $C_{1-6}$alkyl and $C_{1-6}$alkoxy, q is 1, 2 or 3, r is 1, 2, 3 or 4 and D is selected from phenyl, indol-3-yl, indol-4-yl which phenyl may bear one or more substituents selected from fluoro, methyl, ethyl, methoxy, ethoxy or -O-$(CH_2)_2$-O- and which indolyl may bear one or more substituents selected from fluoro, methyl, ethyl, methoxy ~~or ethoxy~~ and ethoxy;

~~*in vivo* hydrolysable precursors thereof, and~~ or a pharmaceutically-acceptable ~~salts~~ salt thereof.

6. (original) A pharmaceutical composition comprising a compound according to Claim 1 together with at least one pharmaceutically-acceptable excipient or diluent.

7. (canceled).

8. (currently amended) A method of treating a disease condition wherein antagonism of $NK_1$ receptors in combination with SRI activity is beneficial ~~which method comprises~~

comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 1 or ~~an *in vivo* hydrolysable precursor or~~ a pharmaceutically-acceptable salt thereof.

9-13. (canceled).

14. (new) A method of treating depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, or post partum depression comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof.

15. (new) A method of treating depression comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof.

16. (new) A method of treating generalized anxiety disorder comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof.

17. (new) A method of treating depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, or post partum depression comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 2 or a pharmaceutically-acceptable salt thereof.

18. (new) A method of treating depression comprising administering to a warm-blooded

animal an effective amount of a compound according to Claim 2 or a pharmaceutically-acceptable salt thereof.

19. (new) A method of treating generalized anxiety disorder comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 2 or a pharmaceutically-acceptable salt thereof.

20. (new) A method of treating depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, or post partum depression comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 3 or a pharmaceutically-acceptable salt thereof.

21. (new) A method of treating depression comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 3 or a pharmaceutically-acceptable salt thereof.

22. (new) A method of treating generalized anxiety disorder comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 3 or a pharmaceutically-acceptable salt thereof.

23. (new) A method of treating depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, or post partum depression comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 4 or a pharmaceutically-acceptable salt thereof.

24. (new) A method of treating depression comprising administering to a warm-blooded

animal an effective amount of a compound according to Claim 4 or a pharmaceutically-acceptable salt thereof.

25. (new) A method of treating generalized anxiety disorder comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 4 or a pharmaceutically-acceptable salt thereof.

26. (new) A method of treating depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, or post partum depression comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 5 or a pharmaceutically-acceptable salt thereof.

27. (new) A method of treating depression comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 5 or a pharmaceutically-acceptable salt thereof.

28. (new) A method of treating generalized anxiety disorder comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 5 or a pharmaceutically-acceptable salt thereof.

29. (new) A method of treating depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, or post partum depression comprising administering to a warm-blooded animal an effective amount of a compound selected from:

1-N-methyl-4-(3,4-dichlorophenyl)-4-((3-cyano-2-methoxynaphth-1-yl)methoxymethyl)piperidine;

4-(4-fluorophenyl)-4-[(3-cyano-2,4-dimethoxynaphth-1-yl)methoxymethyl]piperidine;

4-(4-fluorophenyl)-4-[(3-cyano-2-methoxynaphth-1-yl)methoxymethyl]piperidine;

{2-[4-(3-cyano-2-methoxy-naphthalen-1-yl-methoxymethyl)-4-(4-fluorophenyl)-piperidin-1-yl]-2-oxo-ethyl}-methyl-carbamic acid tert-butyl ester;

4-[4-(4-fluorophenyl)-1-(2-methylamino-acetyl)-piperidin-4-ylmethoxymethyl]-3-methoxy-naphthalene-2-carbonitrile;

4-{4-(4-fluorophenyl)-1-[2-(1H-indol-3-yl)-ethyl]-piperidin-4-ylmethoxymethyl}-3-methoxy-naphthalene-2-carbonitrile;

1-N-methyl-4-(3,4-dichlorophenyl)-4-((3-cyanonaphth-1-yl)methoxymethyl)piperidine;

1-N-methyl-4-(3,4-dichlorophenyl)-4-((3-cyano-2,4-dimethoxynaphth-1-yl)methoxymethyl)piperidine;

1-N-methyl-4-(4-fluorophenyl)-4-((3-cyanonaphth-1-yl)methoxymethyl)piperdine;

4-{[4-fluoro-1-naphthyl)methoxy]methyl}-4-(4-fluorophenyl)-1-methylpiperidine;

4-(4-chlorophenyl)-4-[(3-cyano-2-methoxynaphth-1-yl)methoxymethyl]piperidine;

1-N-methyl-4-phenyl-4-((3-cyanonaphth-1-yl)methoxymethyl)piperidine;

1-N-methyl-4-(4-fluorophenyl)-4-((naphtha-1-yl)methoxymethyl)piperidine;

1-methyl-4-(1-naphthalen-1-yl-ethoxymethyl)-4-phenylpiperidine;

1-N-methyl-4-(4-fluorophenyl)-4-(3-cyano-1-naphthalen-1-yl-ethoxymethyl)piperidine; and

1-N-methyl-4-(4-fluorophenyl)-4-(3-cyano-2,4-dimethoxy-1-naphthalen-1-yl-ethoxymethyl)piperidine; or

a pharmaceutically-acceptable salt thereof.